Insmed Incorporated (NASDAQ:INSM) Stock Holdings Reduced by Axiom Investors LLC DE

Axiom Investors LLC DE cut its position in shares of Insmed Incorporated (NASDAQ:INSM) by 3.8% in the fourth quarter, Holdings Channel reports. The firm owned 83,874 shares of the biopharmaceutical company’s stock after selling 3,340 shares during the period. Axiom Investors LLC DE’s holdings in Insmed were worth $5,791,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC increased its holdings in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC grew its position in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 248 shares in the last quarter. Spire Wealth Management acquired a new position in shares of Insmed during the 4th quarter worth $47,000. Smartleaf Asset Management LLC raised its holdings in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Insmed in the 4th quarter valued at $86,000.

Insider Activity

In other Insmed news, CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the completion of the transaction, the chief executive officer now owns 384,960 shares in the company, valued at $26,885,606.40. This trade represents a 4.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Sara Bonstein sold 1,066 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the sale, the chief financial officer now owns 118,863 shares in the company, valued at approximately $7,573,950.36. This represents a 0.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 550,957 shares of company stock worth $42,992,528. Corporate insiders own 4.60% of the company’s stock.

Insmed Price Performance

Shares of INSM stock opened at $77.99 on Monday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The company has a market capitalization of $14.12 billion, a P/E ratio of -13.95 and a beta of 1.28. The stock has a 50 day moving average of $78.18 and a two-hundred day moving average of $74.00. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, equities analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Analysts Set New Price Targets

Several research firms have commented on INSM. Cantor Fitzgerald reissued an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Guggenheim reissued a “buy” rating and issued a $101.00 price objective on shares of Insmed in a research note on Tuesday, February 25th. Stifel Nicolaus decreased their target price on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.